Target intelligence / Profile preview

ATP-binding cassette sub-family B member 1 (ABCB1) (ABCB1)

Target
ABCB1
Molecular classification
Transporter, ATP-binding cassette (ABC) transporter, ABC-B family
01

Overview

ATP-binding cassette sub-family B member 1 (ABCB1), widely known as P-glycoprotein 1 (P-gp) or multidrug resistance protein 1 (MDR1), is an essential plasma membrane protein that acts as an ATP-dependent efflux pump (UniProt P08183). It is primarily expressed in barrier and excretory tissues, including the intestinal epithelium, liver canalicular membrane, renal proximal tubules, and the endothelial cells of the blood-brain barrier (PubMed: 25700201). Its physiological role is to protect the body by pumping out potentially harmful xenobiotics and toxic metabolites into the gut lumen, bile, or urine (StatPearls). In clinical oncology, ABCB1 is a major driver of multidrug resistance (MDR) because it actively extrudes various chemotherapeutic agents, such as taxanes and vinca alkaloids, from tumor cells, thereby lowering their intracellular concentration and efficacy (NIH/NCI). Additionally, ABCB1 plays a critical role in pharmacokinetics; many common medications are substrates or inhibitors of this transporter, leading to significant drug-drug interactions (PubMed: 30121151). While efforts to therapeutically inhibit ABCB1 to sensitize cancers to treatment have faced clinical challenges, it remains a vital target for understanding drug disposition and toxicity (Wikipedia).

Other names
P-glycoprotein 1Multidrug resistance protein 1MDR1CD243GP170P-gp
02

Mechanism of action

ATP-dependent efflux pump that translocates substrates across the cell membrane against a concentration gradient to the extracellular space (UniProt P08183).

03

Biological functions

Xenobiotic effluxBlood-brain barrier maintenanceRenal excretionIntestinal secretionBiliary excretionSteroid transportLipid translocation
04

Disease associations

Cancer (Multidrug resistance)Alzheimer's diseaseEpilepsyInflammatory bowel diseaseParkinson's disease
05

Safety considerations

Drug-drug interactions (DDI) due to competitive inhibitionIncreased risk of neurotoxicity if blood-brain barrier permeability is alteredSystemic toxicity of co-administered chemotherapy drugsVariable drug bioavailability due to genetic polymorphisms
06

Interacting drugs

Digoxin

9 more in the full profile.

07

Biomarkers

ABCB1 protein expression (IHC)MDR1 mRNA levelsABCB1 C3435T polymorphismRhodamine 123 efflux assay

Beyond the preview

Go deeper on ATP-binding cassette sub-family B member 1 (ABCB1) (ABCB1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-binding cassette sub-family B member 1 (ABCB1) (ABCB1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call